Cell-Based Assays: World Market Prospects 2011-2026
Visiongain
January 19, 2011 127 Pages - SKU: VSG6164924
|
|
Are you looking for pharmaceutical R&D market data - answers to save you time and effort, aiding decisions? Our new report shows you spending trends and revenue prospects for cell-based assays in pharma. We give market data for 2009 to 2026.
There, you will discover commercial prospects for cell assays in drug research, analyses found only in our report. You can benefit by ordering now, staying ahead.
Our report shows market opportunities at global and national levels. You can assess the high growth potential of the cell assay industry and market now.
How will the cell-based assay sector develop from 2011, and where can you find the greatest opportunities? How will technology suppliers and drug developers benefit? What roles are contract research organisations playing in cell assaying?
Our report answers those questions and others for the cellular assays market. We show you where the sector is heading from 2011 - events, technologies and revenues.
We show what leading companies are doing, and how competition is shaping up. You will see emerging trends in drug discovery and development.
Our report is your link to the organisations, ideas and activities that will shape the pharma cell assay sector this decade and beyond.
We show you the areas to watch in cell-based assays. Advances in culturing, handling, automation, detection and probes have opened up new possibilities in drug discovery and compound screening.
In particular, stem cells and 3-D bioassays show potential. You will see how.
Our new report also discusses challenges and uncertainties in the cell testing sector. How will the industry and market develop?
You can assess the sector's strengths, weaknesses, trends and prospects from 2011. You will see opportunities in the sector, benefiting suppliers and users of cell technology.
Here, you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.
Analysis and expert opinion to help your work - so you won't be left behind
Our new report gives you revenue forecasts, growth rates, market share analysis, SWOT analysis, technology reviews and expert opinion. We include 47 tables and charts and two interviews (shown in the accompanying lists). We aim to benefit your analyses and ideas, giving you market information now.
Cell-Based Assays: World Market Prospects 2011-2026 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
- You will discover hard data for the cell-based assays sector - especially our revenue forecasts to 2026
- You will receive the first report of its kind - helping you to stay ahead in cellular assays for pharma research
- You will find spending trends from 2009 to 2026 - globally and nationally - showing you where commercial potential will occur
- You will discover revenue prospects for leading national markets from 2011 to 2026 (US, Japan, UK, Germany, France, Spain, Italy, China and India)
- You will review contract research organisations providing cell-based assay development and screening services
- You will assess leading companies, discovering their activities and outlook
- You will investigate competition and market opportunities in cell-based pharma assays
- You will find out what stimulates and restrains the cell assays industry and market, from the present looking ahead
- You will review cell-based assay technologies, assessing their potential
- You will investigate opportunities for established companies and those seeking market entry
- You will view expert opinion from our survey, including full interview transcripts.
That combination of quantitative and qualitative market analysis sets our report apart. We give you original market predictions, found only in our work.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report
|
Additional InformationCompanies Listed
Acea Biosciences
Actelion Pharmaceuticals
Admet Group
Advanced CellSystems
Agilent
Agilent Automation Solutions
Amnis
Applied BioPhysics
Applied Biosystems
Apredica
Aragen Bioscience
Argenta Discovery
Asterand
AstraZeneca
Attagene
AvantiCell Science
BD Biosciences
Beckman Coulter
BellBrook Labs
Berthold Technologies
BioAgilytix Labs
BIOalternatives
BioCat
Biochrom
Bionas
Biopta
BioTek Instruments
BMG LABTECH
BRI Biopharmaceutical Research
Bristol-Myers Squibb
BURECO
Caliper Discovery Alliances & Services (CDAS)
Caliper Life Sciences
Cambridge Biomedical
Carna Biosciences
Cayman Chemical
Ceetox
Celerion
Cell Biolabs
Cell Signaling Technology
Cellartis
Cellectricon
Cellix
Cellomics
CellSpecific
Cellular Dynamics International
Celsis International
Cerep
Cisbio Bioassays
Corning Incorporated Life Sciences
Covance
Crown Bio Science
CyBio
Cyntellect
Cyprotex
Cytogration
CYTOO
Digilab
DiscoveRx
DiscoveryBiomed
Environmental Protection Agency (EPA)
Enzo Life Sciences
Eppendorf
Essen BioScience
European Collection of Cell Cultures (ECACC)
European Commission (EC)
Evotec
Fluofarma
Food and Drug Administration (US FDA)
Galapagos
GE Healthcare
GenPharmTox Bio Tech
GenScript
Gentronix
Genzyme
GlaxoSmithKline
GlycoMar
Greiner Bio-One
GUNZE Medical Division
Hamamatsu Photonics
Hamilton Robotics
Harlan Laboratories
Hidex
HighRes Biosolutions
Hudson Robotics
ibidi
Inbiolabs
Innoprot
Institute for Biomaterials and Biomedical Engineering, University of Toronto
InTouch BioSolutions
Invitrogen Corporation
IonGate
J-TEC
Labcyte
Label Independent
Life Technologies Corporation
Lonza
Marin Biologic Laboratories
Matrical Bioscience
MatTek Corporation
MB Research Laboratories
MD Biosciences
MDS Analytical Technologies
Meso Scale Discovery
Millipore
Molecular Devices
Nanopoint
Nexcelom Bioscience
Nexus Biosystems
Novartis
NovaScreen Biosciences
Novo Nordisk
Origin Biosciences
Pall Corporation
Paragon Bioservices
Patheon
PerkinElmer
Pestka Biomedical Laboratories
Pharmahungary
Pharmaron
Pharmatest
Platypus Technologies
PREMAS Biotech
Promega Corporation
ProQinase
QPS
R&D Systems
ReachBio
Roche Applied Science
SABiosciences (a Qiagen Company)
SBH Sciences
Scottish Biomedical
Scynexis
Seahorse Bioscience
Shanghai Genomics
Shanghai Medicilon
Sigma-Aldrich
SkinEthic
Solidus Biosciences
SRU Biosystems
Stem Cell Innovations
StembiGen
STEMCELL Technologies
Sugen Life Sciences
SymCel
TCS Cellworks
Tecan
The Automation Partnership
The Institute for Bioanalytics
The Technology Partnership (TTP)
Thermo Fisher Scientific
Toshiba Research Europe
TTP LabTech
Velocity11
World Trade Organization (WTO)
Xactagen
XCellR8
Xenogen Biosciences
XenoTech
- 1. Executive Summary
- 1.1 Cell-Based Assays Market Review
- 1.2 Aims, Scope and Format of the Report
- 1.2.1 Speculative Aspects of Assessing the Cell-Based Assays Market
- 1.2.2 Chapter Outlines
- 1.3 Research and Analysis Methods
- 2. Introduction to Drug Discovery and Drug Screening Assays
- 2.1 Drug Discovery and Development
- 2.2 The Process of Drug Discovery and Development
- 2.3 Important Facts about Drug Candidates
- 2.4 Drug Screening Assays
- 2.5 Types of Drug Screening Assays
- 2.5.1 In-Vivo Assays: Animal Models
- 2.5.2 Biochemical Assays
- 2.5.3 Cell-Based Assays
- 2.6 Use of Screening Assays in Drug Discovery
- 2.6.1 Target Validation and Lead Identification
- 2.6.2 High-Throughput Screening (HTS): A Strong Association with Drug Discovery
- 2.6.3 Toxicity Testing
- 2.6.3.1 Drug Recalls: A Burden for Drug Developers
- 2.6.3.2 Hepatotoxicity and Cardiotoxicity: Common Causes for Drug Recalls
- 2.6.3.3 Lack of Suitable Assays to Predict Drug Toxicity
- 2.7 Bioassay Development: A Challenging Task
- 3. Cell-Based Assays in Drug Discovery
- 3.1 Cell-Based Assays as Important Tools for Drug Discovery
- 3.2 Applications for Cell-Based Assays
- 3.2.1 Target Validation
- 3.2.2 Primary Screening
- 3.2.3 Secondary Screening
- 3.2.4 ADME/Tox Screening
- 3.2.5 High-Throughput Screening and Cell-Based Assays
- 3.3 Key Elements of Cell-Based Assays
- 3.4 Important Considerations for Cell-Based Assays
- 3.5 The Cellular Component: Choosing the Correct Cell Type and Format
- 3.5.1 Immortalised Cell Lines
- 3.5.2 Primary Cells
- 3.5.3 Stem Cells
- 3.6 Assay Format
- 3.6.1 Two-Dimensional (2-D)/Monolayer Assays
- 3.6.2 Limitations of 2-D Assays
- 3.6.3 Three-Dimensional (3-D) Assays
- 3.6.4 Advantages of 3-D Cell Culture
- 3.7 Assay Readout Modality
- 3.7.1 Uniform Well Measurement
- 3.7.2 High-Content Measurement/High-Content Screening
- 3.8 Assay Detection Technology
- 3.8.1 Label-Based Assays
- 3.8.1.1 Reporter Gene Technology
- 3.8.1.2 Resonance Energy Transfer (FRET and BRET)
- 3.8.1.3 Split Complementation Assays
- 3.8.2 Label-Free Assays
- 3.8.2.1 Electrical Biosensor/Impedance Systems
- 3.8.2.2 Optical Biosensor Systems
- 3.8.2.2.1 Resonant Waveguide Grating (RWG) Systems
- 3.8.2.2.2 Surface Plasmon Resonance (SPR) Systems
- 3.8.2.3 Acoustic Biosensor Systems
- 3.8.2.3.1 Resonant Acoustic Profiling (RAP)
- 3.8.3 Other Label-Free Assay Technologies
- 4. Global Market for Cell-Based Assays, 2009-2026
- 4.1 Scope and Limitations
- 4.2 Global Cell-Based Assays Market, 2009 and 2010
- 4.2.1 Current State of the Cell-Based Assays Market
- 4.2.2 Around 1.4% of Global R&D Expenditure was Spent on Cell-Based Assays in 2009
- 4.2.3 Cell-Based Assays Market in 2009 and 2010, by Application
- 4.2.4 Outsourcing of Cell-Based Assays to Contract Research Organisations (CROs)
- 4.3 Expanding Market for Cell-Based Assays
- 4.3.1 Spending on Cell-Based Assays: Global Forecast, 2011-2015
- 4.3.2 Spending on Cell-Based Assays: Global Forecast, 2016-2026
- 4.3.3 Factors Driving the Cell-Based Assays Market
- 4.4 Leading National Markets for Cell-Based Assays, 2010-2026
- 4.4.1 The US Dominates the Global Cell-Based Assay Market
- 4.4.2 The Japanese Cell-Based Assays Market, 2010-2026
- 4.4.3 The Leading European Cell-Based Assays Markets, 2010-2026
- 4.4.4 The Cell-Based Assays Markets in Emerging Economies, 2010-2026
- 4.4.4.1 The Chinese Cell-Based Assays Market, 2010-2026
- 4.4.4.2 The Indian Cell-Based Assays Market, 2010-2026
- 5. Systems, Software, Consumables and Services: Enabling Cell-Based Assays
- 5.1 Products and Services in the Cell-Based Assays Market
- 5.2 Equipment/Systems
- 5.2.1 Microplate Readers
- 5.2.2 Liquid-Handling Systems
- 5.3 Consumables
- 5.4 Disposables
- 5.5 Contract Research Organisations (CROs) Providing Cell-Based Assay Services
- 5.6 Covance
- 5.6.1 Profile
- 5.6.2 Service Offering
- 5.6.3 Financial Performance
- 5.7 CellSpecific
- 5.7.1 Overview
- 5.7.2 Services
- 5.7.2.1 Cell-Based Assays
- 5.7.2.2 Cell Isolation and Differentiation
- 5.8 TTP LabTech
- 5.8.1 Overview
- 5.8.2 Instruments and Consumables for Cell-Based Assays
- 5.8.2.1 Acumen eX3
- 5.8.2.2 RAPid 4 Platform
- 5.8.3 High-Content Screening Services
- 5.8.3.1 Specific Features
- 5.8.4 TTP LabTech Combines with BellBrook Labs to Allow High Throughput Chemotaxis Research
- 5.9 Bionas
- 5.9.1 Profile
- 5.9.2 Instruments and Consumables for Cell-Based Assays
- 5.9.2.1 Bionas Discovery 2500 System
- 5.9.2.2 Bionas Discovery Adcon Reader
- 5.9.3 Contract Service
- 5.10 Invitrogen Corporation
- 5.10.1 Overview
- 5.10.2 Cell-Based Assay Kits
- 5.10.3 Services Related to Cell-Based Assays
- 5.10.3.1 Assay Development Services
- 5.10.3.2 Screening Services
- 5.10.3.3 ADME/Tox Services
- 5.10.4 Financial Performance
- 5.11 Caliper Discovery Alliances & Services (CDAS)
- 5.11.1 Overview
- 5.11.2 Service Portfolio
- 5.11.3 Financial Performance
- 6. Industry Trends
- 6.1 Expansion of Microfluidics Use for Cell-Based Assays
- 6.2 Multiplexing
- 6.3 Going Label-Free
- 6.4 Stem Cell Based Assays
- 6.5 Moving from 2-D to 3-D
- 6.6 Miniaturisation and Automation
- 7. SWOT Analysis of the Cell-Based Assays Market
- 7.1 Strengths and Weaknesses of the Sector
- 7.1.1 In-Vitro Assays are Essential for Drug Discovery
- 7.1.2 Alternatives to Animal Testing
- 7.1.3 Cell-Based Assays are More Biologically Relevant
- 7.1.4 Assay Performance Affected by Multiple Factors
- 7.1.5 Expensive Compared with Biochemical Assays?
- 7.2 Opportunities and Threats
- 7.2.1 Cost Reduction Efforts by Research Sponsors
- 7.2.2 Technological Innovations: Increasing Relevance of Cell-Based Assays
- 7.2.3 Developments in Robotic Systems: Benefiting Cell-Based Assays
- 7.2.4 Gaining Regulatory Acceptance as Stand-Alone Tests
- 8. Expert Opinion from the Sector
- 8.1 Interview with Dr Jussi Halleen, CEO, and Mr Rami Käkönen, Chief Marketing Officer, Pharmatest
- 8.1.1 Cell-Based Assays and Their Application in the Biopharmaceutical Industry
- 8.1.2 Market Size and Growth of the Cell-Based Assays Market
- 8.1.3 Drivers and Inhibitors for the Cell-Based Assays Market
- 8.1.4 Services Offered by Pharmatest
- 8.2 Interview with Mr Rob Chaney, General Manager and COO, ReachBio
- 8.2.1 Cell-Based Assays and Their Application in the Biopharmaceutical Industry
- 8.2.2 Market Size and Growth of the Cell-Based Assays Market
- 8.2.3 Drivers and Inhibitors for the Cell-Based Assays Market
- 8.2.4 The Use of Stem Cells in Cell-Based Assays
- 8.2.5 Latest Trends in the Cell-Based Assays Market
- 8.2.6 Services Offered by ReachBio
- 9. Conclusions
- 9.1 This Market Holds Significant Commercial Potential
- 9.2 Challenges for Cell-Based Assays
- 9.3 Advantages of Cell-Based Assays
- 9.4 Future Outlook and Concluding Remarks
- List of Tables
- Table 2.1 Important Parameters for a Drug Candidate
- Table 2.2 Some Drugs Withdrawn Because of Toxicity Concerns, 1991-2010
- Table 3.1 Advantages and Disadvantages of Reporter Gene Technology for Cell-Based Assays
- Table 3.2 Companies Providing Label-Free Cell-Based Assay Systems, 2010
- Table 4.1 Global Cell-Based Assays Market ($bn), 2009
- Table 4.2 Global Cell-Based Assays Market ($m) by Application, 2009 & 2010
- Table 4.3 Spending on Products and Services in the Cell-Based Assays Market ($m), 2009 & 2010
- Table 4.4 Shares (%) of Spending on Products and Services in the Cell-Based Assays Market, 2009 & 2010
- Table 4.5 Global Cell-Based Assays: Spending Forecast ($bn, AGR & CAGR %), 2009-2018
- Table 4.6 Global Cell-Based Assays: Spending Forecast ($bn, AGR & CAGR %), 2019-2026
- Table 4.7 Cell-Based Assays: Global and Regional Spending Forecasts ($m), 2009-2018
- Table 4.8 Cell-Based Assays: Global and Regional Spending Forecasts ($m), 2019-2026
- Table 4.9 Market Shares (%) of the Nine Leading National Markets, 2010, 2015, 2020 & 2026
- Table 5.1 Companies Providing Detection Equipment for Cell-Based Assays, 2010
- Table 5.2 Commercially-Available Robotic Systems for Liquid Handling and Cell Culture, 2010
- Table 5.3 Companies Providing Commercial Cell-Based Assay Kits, 2010
- Table 5.4 Companies Providing Primary Cells, Cell Lines or Stem Cells, 2010
- Table 5.5 Companies Providing Microplates for Cell-Based Assays, 2010
- Table 5.6 CROs Providing Cell-Based Assay Development and Screening Services, 2010
- Table 5.7 Covance Revenue ($m), 2008 and 2009
- Table 5.8 Invitrogen's Cell-Based Assays, 2010
- Table 5.9 Life Technologies Corporation Revenue ($m), 2008 and 2009
- Table 5.10 Caliper Life Sciences Revenue ($m), 2008 and 2009
- Table 6.1 Microfluidic Systems for Cell-Based Assays, 2010
- Table 6.2 Drivers and Restraints for Adoption of Label-Free Cell-Based Assays, 2011
- Table 7.1 SWOT Analysis of the Cell-Based Assays Market, 2011
- Table 7.2 Commercially-Available Skin Models, 2010
- List of Figures
- Figure 2.1 Phases in Drug Discovery and Development
- Figure 2.2 Number of Drug Recalls by the FDA, 2006-2010
- Figure 4.1 Cell-Based Assays: Global Market Shares (%) by Application, 2009
- Figure 4.2 Cell-Based Assays: Global Market Shares (%) by Application, 2010
- Figure 4.3 Spending ($m) on Products and Services in the Cell-Based Assays Market, 2009 & 2010
- Figure 4.4 Shares (%) of Spending on Products and Services in the Cell-Based Assays Market, 2009
- Figure 4.5 Shares (%) of Spending on Products and Services in the Cell-Based Assays Market, 2010
- Figure 4.6 Cell-Based Assays: Global Spending Forecast ($bn), 2009-2026
- Figure 4.7 US and Japan: Cell-Based Assay Spending Forecasts ($m), 2009-2026
- Figure 4.8 Europe, India and China: Cell-Based Assay Spending Forecasts ($m), 2009-2026
- Figure 4.9 Cell-Based Assays: Spending Shares (%) by Country, 2010
- Figure 4.10 Cell-Based Assays: Spending Shares (%) by Country, 2015
- Figure 4.11 Cell-Based Assays: Spending Shares (%) by Country, 2020
- Figure 4.12 Cell-Based Assays: Spending Shares (%) by Country, 2025
- Figure 5.1 Cell-Based Assay Market Model, 2011
- Figure 5.2 Bioanalytical Services Provided by Covance, 2010
- Figure 5.3 Covance Revenue Shares (%) by Segment, 2009
- Figure 5.4 Life Technologies Corporation Revenue Shares (%) by Segment, 2008 and 2009
- Figure 5.5 Caliper Life Sciences Revenue Shares (%) by Segment, 2008 and 2009
- Figure 9.1 Drivers for Adoption of 3-D Cell-Based Assays, 2011
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
